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ABSTRACT  (267 words) 
Objective: To examine the impact, on three quality indicators of end-of-life (EOL) care, of 
oncologist’s awareness in palliative care (PC), timing of the PC team (PCT) intervention, and 
multidisciplinary decision-making thanks to weekly onco-palliative meetings (OPMs).  
Setting: France, Cochin academic hospital, 2007-2008 
Design and participants:  a 521 decedent case series study nested in a cohort of 735 
metastatic cancer patients previously treated with chemotherapy.  
Indicators : Location of death, number of emergency room (ER) visits within one month 
preceding death and administration of chemotherapy in last 14 days of life. Multivariable 
logistic regression models were used to estimate associations between indicators and 
oncologist’s awareness in PC, intervention of PCT, case discussion at OPMs. 
Results: Location of death was home for 58 (11%) patients, ICU or emergency room for 45 
(9%), acute care hospital for 253 (49%); 185 (36%) patients visited emergency room within 1 
month before death, and 75 (14%) received chemotherapy within  14 days before death. Only 
the OPM (n=179,34%) independently decreases the odds of receiving chemotherapy in last 14 
days of life (OR[CI95%]:0.5[0.2;0.9]) and the odds of dying at hospital (excluding hospice) 
0.3[0.1.;0.5]). Oncologist’s awareness in PC (n=184, 35%) and intervention of the PC team 
(n=300, 58%) did not improve independently any indicators. Among patients seen by PCT, 
median survival after first contact was longer for patients discussed at OPM (75 days) than for 
those not discussed (29 days). In multivariable analysis, the OPM remains more determinant 
than survival after first contact to decrease death at hospital. 
Conclusion: Multidisciplinary decision-making with referent physician and palliative team is 
the most critical parameter to improve EOL care. 
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INTRODUCTION 
Considerable attention is currently being focused on the impact of integration of palliative 
care (PC) in oncology [1]. In cancer centres, late referral of patients to specialist PC reflects 
the persistent barriers to integrated palliative care in oncology [2]. Temel et al. showed that 
early PC consultation systematically offered to patients diagnosed with advanced non-small 
cell lung cancer (NSCLC) increased both their survival and quality of life [3]. This study 
marks a turning point for the integration of PC, pointing out the value of early introduction of 
the PC team. However, the factors accounting for these results are unclear.  
Various models of organisation, intervention and interface of specialist PC with standard care 
have developed across countries. Efforts to systematically review evidence for effectiveness 
of PC services lead to ambivalent conclusions, mainly due to insufficient internal and external 
validity of original studies [4-6]. In their study focusing on “the effectiveness of specialist PC 
delivered to cancer patients”, Higginson et al. state the wide range of services tested, 
concluding that future studies need to test more specific components of PC team activity [4].  
In France, most developed PC services remain hospital based, with inpatient PC centres or 
hospital PC teams. These teams act as staff counsellors at the patient’s bedside in end-of-life 
situations. They concentrate efforts on the acculturation of the medical and nursing staff being 
directly in charge of patients. In oncology, this mode of intervention respects the oncologist’s 
role, but its impact on the patient is indirect and highly depends on the degree of organisation 
and collaboration between both specialties.  
In our institution, the PC team has developed a collaborative organisation with the oncology 
ward in order to reduce persistent barriers and improve the quality of end of life care. This 
collaboration is based on a weekly onco-palliative meeting (OPM) attended by both the PC 
team and the oncology staff, who discuss the cases of any advanced cancer patients who could 
benefit from joint follow-up care. We hypothesized that this OPM, as a key component of the 
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PC team activity, may be as important as the on-demand intervention of PC team to improve 
indicators of quality of end of life care.  
Many indicators have been proposed to describe the quality of both outcomes and processes 
of end-of-life care (i.e. use of health services resources) [7]. In order to estimate the impact of 
the different modalities of introducing palliative care in the trajectory of cancer patients, we 
chose process of care indicators. Those developed and evaluated by Earle et al. address three 
aspects of care [8, 9]: overuse of aggressive treatment resources, unplanned medical 
encounters, and poor access to PC. 
In the present study, we evaluated the impact of oncologist’s awareness in PC, clinical 
intervention of PC team and its timing, multidisciplinary decision-making on the end-of-life 
care indicators described by Earle et al.[8] 
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METHODS 
Design and setting 
Cochin Hospital is a tertiary care hospital treating 6,000 new cancer patients each year, with 
an oncology department and 3 other medical specialty wards (gastroenterology, pneumology, 
dermatology) dispensing chemotherapy. We conducted a decedent case series study, using a 
mortality follow-back approach. Decedent cases were identified by follow-up of all eligible 
patients recorded in the hospital activity data.  
Study population  
All patients diagnosed with solid tumour and having received their last administration of 
intravenous chemotherapy at Cochin hospital, between June 1st, 2006 and December 31st 2008 
were considered eligible for inclusion in our case series. These patients were identified from 
the electronic record database (CHIMIO) routinely used to manage patients receiving 
intravenous chemotherapy.  
Patient vital status was identified in three steps. We first cross-matched the CHIMIO database 
of eligible patients with the hospital discharge data (2007-2008) of 30 acute care hospitals in 
the Paris area. Then, for patients not recorded to be deceased at discharge, we searched these 
patients’ medical records for a posteriori notification of death. Finally, we completed follow-
up by combining requests to civil administrative services, and telephone interview of the 
patient’s referring primary care physician. All patients deceased during the study period were 
included. 
Organisation of care 
Chemotherapy is prescribed by either the 5 physicians of the oncology ward or the 10 other 
specialists from other wards qualified in oncology. None of these physicians are involved in 
palliative care practice, but some of them followed a training program introducing the 
fundamentals of palliative care, thereby increasing their awareness of palliative care services. 
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The patient is then recorded in the CHIMIO database. All 15 prescribers are designated later 
on as “referent physician”. The PC team consists in 2.5 full time equivalent physicians, all PC 
specialists, 2.5 full time equivalent nurses, 1 secretary assistant, 1 attending psychologist.  
There are two different ways of referral to the PC team. One existing with oncology ward, 
relies on a weekly Onco-Palliative multidisciplinary Meetings (OPM), dedicated to patients 
deemed incurable and for whom it is necessary to discuss goals of care. The OPM is lead by a 
physician of the PC team who also records its conclusions in patient’s record. It is attended by 
both the PC team and the oncology staff, i.e. physicians, nurses and head nurses, social 
workers, psychologists, and secretaries [10]. Patient eligibility for discussion at the OPM is 
defined by a life expectancy shorter than 6 month, as estimated by the referent physician, who 
thereby initiates discussion. Discussions take into account expected benefit on survival and 
quality of life, aggressiveness of care, and patient’s preferences. Decisions may be to pursue 
chemotherapy, associated or not with intervention of the PC team, to propose inclusion in a 
phase 1 or 2 clinical trial, or to provide PC only. These decisions are then submitted to the 
patient’s wishes. Later on, patients are followed-up jointly by the PC team and the referent 
physician, and goals of care are updated at following OPMs. Follow-up of patients is made 
possible, as needed, through outpatient consultations (with the referent physician and/or with 
the PC team), in day care setting or by admission in acute care setting. 
Besides this organized activity supporting an integrated model of care, the PC team also 
intervenes, upon the request of health professionals from clinical wards, according to their 
appreciation and without a specific dedicated time, as the OPM, for multidisciplinary 
decision-making. The intervention addresses symptom management, end-of-life care 
decisions, coping with a life-threatening illness, illness and prognostic understanding, 
organisation of referral to hospice, coordination with home care services and networks, or 
outpatients follow-up.  
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Quality indicators 
We evaluated five indicators inspired from those elaborated and validated by Earle et al. [8, 
9]: location of death (acute care setting versus home or hospice), number of emergency room 
(ER) visits within 1 month preceding death (at least one), interval between the last 
administration of chemotherapy and death (less than 14 days), number of admissions in ICU 
and number of acute care admissions, within 1 month preceding death. The two last indicators 
were measured to test their interrelationships with the three first ones. 
 Data collection of history of care 
Other collected data were age, gender, cancer primary site and three process characteristics: 
training of referent physician in PC (reflecting his/her actual degree of awareness in PC), 
whether or not the patient case was discussed at the OPM, intervention or not of the PC team. 
For patients who had been followed by PC team, we recorded performance status (PS), 
according to ECOG scale [11], at the time of this first intervention and time interval between 
first intervention of the team and death  
History of care data and quality indicators were collected from computerized clinical 
databases, completed by search of paper records and interview of referent physicians. 
Statistical Analysis 
Location of death (at hospital, excluding hospice versus other location), referral to emergency 
services (1 or more referrals versus none) and the proportion of patients receiving 
chemotherapy in the last 14 days of life were analysed using logistic regression models. We 
measured the association of these indicators with history of care (including other indicators), 
using odds ratio with 95% Confidence Intervals (95%CIs). For continuous variables, the 
linearity of log-odds was checked graphically. The relationships between the quality 
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indicators and the colinearity between categorical variables were checked using the Cramer’s 
V coefficient (a measure of association derived from the Pearson chi-square). 
All associations with indicators were studied in both univariable and multivariable analyses. P 
value<0.05 was considered significant. The goodness-of-fit of the logistic multivariable 
regression models was tested using the Hosmer-Lemeshow test (small p-values indicate a lack 
of fit of the model). The statistical software SAS (release 9.1; SAS Institute Inc., Cary, NC, 
USA) was used for all analyses. 
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RESULTS 
Study population 
We identified 735 advanced cancer patients who received chemotherapy during the study 
period (figure 1): 105 (14%) were not eligible because they were not dead by the end of the 
pre-defined study period or because they were followed up and cared for in another hospital 
shortly after diagnosis (i.e. patients choosing to be followed in another cancer centre). For 109 
other patients (14.8%), whose vital status could not be found in hospital records, the place of 
birth was either outside France (n=42) or was not informed in hospital admission data (n=67), 
thus preventing from any request to civil services for vital status. Therefore, we finally 
analysed 521 patients whose characteristics and history of care are described in table 1 and 
figure 2.  
 
Table 1: Patients characteristics and history of care  
 Total, N = 521 
Mean age at death, years (SD) 64 (13) 
Sex, n(%)   
    Male 326 (62.6) 
    Female 193 (37.0) 
    Missing data 2 (0.4) 
Primary Cancer site, n (%) 
     Gastro-intestinal 
     Lung 
     Urologic 
     Melanoma 
     Liver and biliary tract 
     Other 
 
110 
107 
67 
67 
52 
118 
 
(21) 
(21) 
(13) 
(13) 
(10) 
(23) 
Location of death, n (%)    
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    Acute care hospital medicine  253 (49) 
    Hospice  128 (25) 
    Home  58 (11) 
    Emergency room or ICU 45 (9) 
    Other  34 (7) 
    Missing data 3 (1) 
History of care; n (%)   
Referent oncologist trained in palliative care    YES 184 (35) 
                                                                            NO    337 (65) 
Palliative care team intervention           YES 300 (58) 
                                                               NO    221 (42) 
     if yes, patient performance status* at inclusion:     1                                                                        
                                                                                     2 
                                                                                     3 
                                                                                     4 
                                                                                     Missing data 
38
72 
78 
43 
69 
(13)
(24) 
(26) 
(14) 
(23) 
      if yes, median survival from inclusion  ; days (IQR) 51 (17-114) 
Onco - palliative meeting (OPM)               YES 179 (34) 
                                                                      NO    341 (66) 
Median survival after last chemotherapy, days (IQR) 55 (25-109) 
Patients receiving chemotherapy in the last 14 days of life, n (%) 
 
75 (14%) 
Emergency room visits, within last 30 days, n (%)   
        0 329 (63) 
        1 160 (31) 
        ≥ 2 25 (5) 
       Missing data  7 (1) 
Admissions in ICU, within last 30 days, n (%)   
        0 459 (88) 
        1 40 (8) 
        ≥ 2 9 (2) 
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       Missing data  13 (2) 
        If ≥ 1, median length of stay, days (IQR) 5 (3-11) 
Admissions in acute care setting, within 30 last days, n (%)   
        0 123 (24) 
        1 242 (46) 
        ≥ 2 97 (19) 
       Missing data  59 (11) 
        If ≥ 1, median length of stay, days (IQR) 14 (8-22) 
* Performance status, as measured by the ECOG [11] http://www.ecog.org/general/perf_stat.html]  :  0 : Fully 
active, able to carry on all pre-disease performance without restriction; 1: Restricted in physically strenuous 
activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office 
work; 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more 
than 50% of waking hours; 3: Capable of only limited selfcare, confined to bed or chair more than 50% of 
waking hours; 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair. 
 
Description of indicators  
Location of death was at home for 58 (11%) patients, hospice for 128 (25%), ER or ICU for 
45 (9%) and acute care wards for 253 (49%). Among the 58 patients who died at home, 17 
(34%) died less than 7 days after their last hospital discharge. Among the 128 patients who 
died in hospice, 14 (11%) died less than 3 days after admission. Among the 253 patients who 
died in acute care wards, 126 (42%) had been admitted after visiting the ER (unscheduled 
hospitalisation) 
Within their last month of life, 185 (36%) patients visited ER at least once, 49 (10%) were 
admitted to ICU, 242 (46%) were hospitalized once in an acute care setting and 97 (19%) 
twice or more. 
The median survival after the last administration of chemotherapy was 55 days (Inter-Quartile 
Range (IQR):25-109); 75 (14%) patients received chemotherapy in their last 14 days of life.  
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Description of history of care 
Patients were followed by 15 referent physicians. Two of them had followed sensibilisation 
training in PC and were referent for 101 and 83 patients respectively (35% overall), whereas 
13 doctors with no training in PC each took care of a median number of 16 patients (min-max 
1-80).  
The PC team collaborated to the care for 67/101 (66%) and 51/83 (61%) patients from the 2 
PC qualified physicians versus 182/337 (54%) patients of the 13 other referent doctors. 
Among the 300 patients taken on by the PC team, PS was recorded in 231; 110 (48%) patients 
had a PS of 1 or 2. The median survival after first referral was 51 days. The first contact with 
the PC team occurred within the last month in a total of 108 (40%). Patients discussed at the 
OPM (143/300) had a better PS than those not discussed (157/300): PS was <2 in 74/143 
(52%) in patients discussed at the OPM, versus in 36/157 (23%) out of the OPM (p< 0.001, 
Chi-Square test). Discussion at the OPM resulted in earlier entry of the PC team: median 
survival was 75 days (IQR: 31-182) in discussed patients, versus 29 days (IQR: 6.5–80) in 
patients not presented at the OPM (p< 0.001, Wilcoxon test).  
Analysis of location of death 
In univariable analyses (table 2), the odds of dying at hospital (excluding hospice) was 
significantly decreased by the following variables: PC training of referent oncologist’s, 
intervention of the PC team, discussion of the patient’s case at the OPM, survival after the last 
chemotherapy longer than 60 days. Conversely, and not surprinsingly, this odds was 
significantly increased with the number of visits to emergency room, and admission to ICU or 
to acute care hospital. Median survival after the last chemotherapy was 77 days (IQR: 45-142) 
in patients who died at home or in hospice and 44 (IQR:19-89) for others.  
After adjusting for all variables, only the patient’s case discussion at the OPM decreases the 
odds of patients who died at hospital (excluding hospice) by 70% (adjusted OR=0.3 
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[CI95%:0.1; 0.5],p<0.001). Other indicators remained significantly associated with death at 
hospital, after adjustment, were ER visits (adjusted OR=2.8 [CI95%:0.8; 9.8], p=0.022) and 
acute care admissions (global p<0.001; adjusted OR = 8.3 [CI95%:4.2; 16.4] for 1 admission; 
OR = 16.2 [CI95%:5.9; 44.6] for 2 or more admissions); 
In the subgroup of 300 patients followed by the PC team, the time between first intervention 
of PC team and death and the OPM are both significantly associated with the odds of dying at 
hospital, whereas the performance status at first evaluation by the PC team was not. In 
multivariable analysis, only the OPM still decreased this odds by 80% (adjusted OR=0.2 
[CI95%:0.1; 0.5], p=0.002) 
 
Analysis of the use of emergency resources 
No process characteristics significantly decreased the proportion of patients visiting ER at 
least once in the last 30 days of life, neither in univariable nor in multivariable analyses (table 
3). Among other indicators, admission to ICU, and survival after last chemotherapy were not 
associated significantly with ER visits contrary to acute care admissions which remain 
significantly associated in multivariable analyses (global p<0.001) (table 3), although patients 
could also be admitted directly in acute care wards.  
Among the 300 patients followed by the PC team, the PS was the only variable associated 
with the use of emergency services in multivariable analyses: altered PS (3 or 4) doubles the 
odds of visiting ER at least once (adjusted OR=2.1 [CI95%:1.0; 4.4], p=0.038). Moreover, 
survival after the first contact with PC team was not statistically associated with referral to 
emergency services. These results are consistent with a referral to emergency services for 
transient, unexpected, acute complication, rather than as the way of managing end-of-life 
care. 
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Analysis of patients receiving chemotherapy in the last 14 days of life 
Median survival after last chemotherapy for patients followed by either PC trained or non 
trained referent physicians, was 76 and 49 days.  
In univariable analyses (table 4), both the intervention of PC team and the discussion of 
patient’s case at the OPM significantly decrease the odds of receiving chemotherapy in the 
last 14 days of life. In multivariable analyses, the OPM still decreased by 50% (OR=0.5 [IC 
95%: 0.2 – 0.9], p=0.035) the odds of receiving chemotherapy in the last 14 days of life. 
Among the 300 patients followed by the PC team, the OPM was the only factor reducing the 
odds of receiving chemotherapy in the last 14 days of life by 60%, in univariable analyses, but 
this effect did not reach statistical significance in multivariable analysis (adjusted OR=0.4 [IC 
95%: 0.1 – 1.2] p=0.089). 
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Table 2:  Location of death, univariable and multivariable logistic regression analyses. 
  Hospital 
(excluding 
hospice) 
Other Univariable analysis,   Multivariable analysis, 
  
N = 332 N = 186  OR‡ (95%CI) P   Adjusted OR‡ (95%CI) P 
All patients        Hosmer & Lemeshow 
Goodness-of-Fit Test† 0.44† 
Mean age at death (years) (SD) 64 (13) 64 (14) 0.99 (0.87 - 1.14)$  0.92 1.00 (0.83 - 1.21)$ 0.98 
Sex, n (%)           
     Females£ 127 (38) 66 (35) 1.0 -  1.0 -  
     Males  204 (61)  119 (64) 0.9 (0.6 - 1.3) 0.54 0.6 (0.4 – 1.1) 0.102 
Primary Cancer site, n (%)      Global p 0.08  Global p 0.90 
     Melanoma £ 48 (15) 19 (10) 1.0 -  1.0 -  
     Gastro-intestinal 75 (23) 34 (18) 0.9 (0.4 – 2.0) 0.69 1.0 (0.3 - 2.9) 1.00 
     Lung 69 (21) 38 (20) 0.7 (0.3 – 1.6) 0.33 1.1 (0.3 - 3.4) 0.99 
     Urologic 33 (10) 33 (18) 0.4 (0.2 – 0.9) 0.011 1.5 (0.4 – 5.5) 0.79 
     Other 107 (32) 62 (33) 0.7 (0.3 – 1.5) 0.23 1.1 (0.4 - 3.2) 0.99 
History of care; n (%)           
Referent oncologist trained in palliative care, n (%)           
    No£ 237 (71) 99 (53) 1.0 -  1.0 -  
    Yes 95 (29) 87 (47) 0.5 (0.3 - 0.7) <0.001 1.1 (0.6 - 2.0) 0.72 
Palliative care team intervention           
    No£ 152 (46) 67 (36) 1.0 -  1.0 -  
    Yes 180 (54) 119 (64) 0.7 (0.5 - 1.0) 0.031 0.7 (0.4 - 1.3) 0.25 
Onco - palliative meeting           
    No£ 259 (78) 81 (44) 1.0 -  1.0 -  
    Yes 73 (22) 105 (57) 0.2 (0.2 - 0.3) <0.001 0.3 (0.1 - 0.5) <0.001 
Survival after last chemotherapy,         Global p <0.001  Global p 0.18 
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  Hospital 
(excluding 
hospice) 
Other Univariable analysis,   Multivariable analysis, 
  
N = 332 N = 186  OR‡ (95%CI) P   Adjusted OR‡ (95%CI) P 
     < 14 days £ 62 (19) 13 (7) 1.0 -  1.0 -  
     [14, 30[       55 (17) 18 (10) 0.6 (0.3 – 1.6) 0.28 0.5 (0.2 – 1.8) 0.41 
     [30, 60[       96 (29) 35 (19) 0.6 (0.2 – 1.3) 0.128 0.8 (0.3 - 2.5) 0.93 
      ≥ 60 days    119 (36) 120 (65) 0.2 (0.1 – 0.4) <0.001 0.5 (0.2 - 1.3) 0.20 
Emergency room visit  (at least one within last 30 days)           
    No£ 181 (55) 147 (79) 1.0 -  1.0 -  
    Yes 147 (44) 38 (20) 3.1 (2.1 - 4.8) <0.001  2.8 (0.8 - 9.8) 0.022 
ICU admission  (at least one within last 30 days)           
    No£ 277 (83) 181 (97) 1.0 -  1.0 -  
    Yes 46 (14) 3 (2) 10.0 (3.1 - 32.7) 0.001 0.4 (0.1 - 1.3) 0.109 
Acute care admission (within last 30 days)      Global p <0.001  Global p <0.001 
     None £ 27 (8.1) 95 (51) 1.0 -  1.0 -  
     1 admission  184 (55) 58 (31) 11.2 (6.6 - 18.8) <0.001 8.3 (4.2 - 16.4) <0.001 
     ≥ 2 admissions  86 (26) 11 (6) 27.5 (12.9- 58.8) <0.001 16.2 (5.9 - 44.6) <0.001 
Patients followed by PC team 
   (N=180)    (N=119)       
 Hosmer & Lemeshow 
Goodness-of-Fit Test† 
0.87† 
Survival after 1st intervention of PC team, median (Q1-
Q3)  
30 (7 – 86) 82 (33 – 179) 1.0 (0.9 – 1.0)* 0.001 1.0 (0.96 – 1.02)* 0.49 
Onco - palliative meeting (OPM)           
     No£ 124 (69) 33 (28) 1.0  -   1.0 -   
    Yes 56 (31) 86 (72) 0.2 (0.1 – 0.3) <0.001 0.2 (0.1 – 0.5) 0.002 
Performance status at first intervention of PC team            
    1-2£ 53 (45) 56 (31) 1.0 -  1.0 -  
    3-4 49 (41) 72 (40) 1.4 (0.8 – 2.3) 0.22 0.7 (0.3 – 1.7) 0.47 
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‡ Odds Ratio for death at Hospital (excluding hospice) versus Other. For multiple comparisons testing difference with the reference category (primary cancer 
site, survival after last chemotherapy, acute care admission), p-values were adjusted using Dunnett correction. For the subgroup of patients followed by PC 
team, the multivariable logistic regression models included age, gender, primary cancer site, and training of referent physician in PC. 
† The null hypothesis cannot be rejected, indicating that the model fits the data (small p-values indicate a lack of fit of the model). 
$ for 10 years increase of age. 
£ Reference category for univariable and multivariable logistic regression. For cancer site, we chose the cancer site with the lowest risk of dying at home or 
hospice as reference category in order to facilitate interpretation (odds ratio greater than one). In univariable analysis, this category was “melanoma” and we 
used it as reference category for all analyses. 
* for 14 days increase of survival. 
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Table 3:  Use of emergency services within last 30 days, univariable and multivariable logistic regression analyses. 
   
At least one visit 
to ER (n = 185) 
 
None 
(n = 329) 
 
Univariable analysis,  
OR‡ (95%CI) 
  
P  
 
Multivariable analysis,  
Adjusted OR‡ (95%CI) P 
All patients         Hosmer & Lemeshow 
Goodness-of-Fit Test† 0.26 
Mean age at death (years) (SD) 64 (13) 64 (13) 0.99 (0.86 - 1.13)$  0.88 0.93 (0.79 - 1.10)$ 0.40 
Sex, n (%)           
   Females £ 59 (32) 132 (40) 1.0 -  1.0 -  
   Males  125 (68) 196 (60)  1.4 (0.98 - 2.1) 0.067 1.2 (0.7 - 1.9) 0.48 
Primary cancer site, n (%)      Global p 0.04  Global p 0.007 
   Melanoma £ 14 (8) 53 (16) 1.0 -  1.0 -   
   Gastro-intestinal 35 (19) 73 (22) 1.8 (0.8 – 4.3) 0.102 2.2 (0.8 - 5.9) 0.147 
   Lung 45 (24) 61 (19) 2.8 (1.2 - 6.6) 0.004 3.2 (1.2 -8.8) 0.018 
   Urologic 26 (14) 39 (12) 2.5 (1.0 - 6.5) 0.018 5.4 (1.7 – 17.3) 0.002 
   Other 65 (35) 103 (31) 2.4 (1.1 – 5.4) 0.010 3.4 (1.3 – 8.8) 0.007 
History of care; n (%)           
Referent oncologist trained in palliative care           
    No £ 116 (63) 217 (66) 1.0 -  1.0 -  
   Yes 69 (37) 112 (34) 1.2 (0.8 - 1.7) 0.46 1.9 (1.1 - 3.2) 0.016 
Palliative care team intervention           
    No £ 79 (43) 136 (41) 1.0 -  1.0 -  
   Yes 106 (57) 193 (59)  1.0 (0.7 - 1.4) 0.76 0.8 (0.5 -1.3) 0.37 
Onco - palliative meeting (OPM)           
    No £ 125 (68) 212 (64) 1.0 -  1.0 -  
   Yes 60 (32) 117 (36) 0.9 (0.6 - 1.3) 0.47 0.8 (0.5 -1.4) 0.45 
Survival after last administration of           
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At least one visit 
to ER (n = 185) 
 
None 
(n = 329) 
 
Univariable analysis,  
OR‡ (95%CI) 
  
P  
 
Multivariable analysis,  
Adjusted OR‡ (95%CI) P 
chemotherapy,   Global p 0.11 Global p 0.078 
     < 14 days £ 24 (13) 49 (15) 1.0 -  1.0 -  
     [14, 30[       30 (16) 43 (13) 1.4 (0.6 – 3.2) 0.30 1.8 (0.7 – 4.4) 0.28 
     [30, 60[       56 (30) 74 (22) 1.5 (0.8 – 3.1) 0.155 2.6 (1.1 – 6.0) 0.025 
     ≥ 60 days    75 (41) 163 (50) 0.9 (0.5 - 1.8) 0.83 1.7 (0.8 - 3.7) 0.26 
ICU admission (at least one within last 30 days) 24 (14) 24 (7) 2.1 (1.1 - 3.7) 0.017 0.9 (0.5 - 1.9)  
Acute care admission (within last 30 days)      Global p <0.001  Global p <0.001 
     None £ 18 (10) 105 (32) 1.0 -  1.0 -  
     1 visit  101 (55) 141 (43) 4.2 (2.2 - 7.8) <0.001 5.2 (2.6 – 10.3) <0.001 
     ≥ 2 visits  58 (31) 39 (12) 8.7 (4.2 - 17.8) <0.001 14.0 (6.0 – 32.5) <0.001 
Patients followed by PC team 
 (n=106)  (n=193)    
 Hosmer & Lemeshow 
Goodness-of-Fit Test† 
0.94 
Survival after 1st intervention of PC team, 
median (Q1 – Q3) 
 
36  
 
(13 – 88) 
 
56 
 
(19 – 129) 
 
0.99 
 
(0.97 – 1.02)* 
 
0.47 
 
1.01 
 
(0.98 – 1.04)* 
0.59 
Onco - palliative meeting (OPM), n (%)           
    No £ 56 (53) 101 (52) 1.0 -  1.0 -  
   Yes 50  (47) 92 (48) 1.0 (0.6 – 1.6) 0.93 1.2 (0.5 – 2.6) 0.71 
Performance status at first intervention of PC 
team  
          
   1-2 £ 36 (34) 73 (38) 1.0 -  1.0 -  
   3-4 51 (48) 70 (36) 1.5 (0.9 – 2.5) 0.155 2.1 (1.0 – 4.4) 0.038 
‡ Odds Ratio for at least one visit in emergency services within last 30 days versus None. For multiple comparisons testing difference with the reference 
category (primary cancer site, survival after last chemotherapy, acute care admission), p-values were adjusted using Dunnett correction. For the subgroup of 
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patients followed by PC team, the multivariable logistic regression models included age, gender, primary cancer site, and training of referent physician in PC. 
† The null hypothesis cannot be rejected, indicating that the model fits the data (small p-values indicate a lack of fit of the model). 
$ for 10 years increase of age. 
£ Reference category for univariable and multivariable logistic regression. For cancer site, we chose the cancer site with the lowest risk of dying at home or 
hospice as reference category in order to facilitate interpretation (odds ratio greater than one). In univariable analysis, this category was “melanoma” and we 
used it as reference category for all analyses. 
* for 14 days increase of survival 
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Table 4: Patients receiving chemotherapy in the last 14 days of life, univariable and multivariable logistic regression analyses 
  Chemotherapy 
in the last 14 
days of life   
No chemotherapy 
in the last 14 days 
of life 
Univariable analysis,  
OR‡ (95%CI) 
  Multivariable analysis,  
Adjusted OR‡ (95%CI) 
 
 (n = 75) (n = 446) P  P 
All patients         Hosmer & Lemeshow 
Goodness-of-Fit Test 0.93† 
Mean age at death (years) (SD) 66 (11) 64 (13) 1.0 (0.9 – 1.0) $  0.29 1.03 (0.8 – 1.3) $ 0.79 
Sex, n (%)           
    Females£ 30 (40) 163 (37) 1.0 -  1.0 -  
    Males  44 (59) 282 (63)  1.2 (0.7 – 2.0) 0.52 1.1 (0.7 – 1.9) 0.64 
Primary Cancer site, n (%)      Global p 0.35  Global p 0.34 
    Melanoma £ 5 (7) 62 (14) 1.0 -  1.0 - 
 
    Gastro-intestinal 18 (24) 92 (21) 2.4 (0.9 - 6.9) 0.095 2.2 (0.6 – 8.0) 
0.33 
    Lung 17 (23) 90 (20) 2.3 (0.8 - 6.7) 0.112 2.7 (0.7 – 10.2) 0.174 
    Urologic 7 (9) 60 (13) 1.5 (0.4 - 4.8) 0.55 1.8 (0.4 – 8.3) 0.70 
    Other 28 (37) 142 (32) 2.4 (0.9 – 6.6) 0.079 2.7 (0.8 – 9.5) 0.141 
History of care; n (%)          
 
Referent oncologist trained in palliative 
care 
         
 
    No£ 52 (69) 285 (64) 1.0 -  1.0 -  
    Yes 23 (31) 161 (36) 0.8 (0.5 - 1.3) 0.36 0.9 (0.5 – 1.7) 0.85 
Palliative care team intervention           
    No£ 43 (57) 178 (40) 1.0 -  1.0 -  
    Yes 32 (43) 268 (60)  0.5 (0.3 – 0.8) 0.005 0.6 (0.4 – 1.1) 0.116 
Onco - palliative meeting (OPM)           
    No£ 60 (80) 282 (63) 1.0 -  1.0 -  
    Yes 15 (20) 164 (37) 0.4 (0.2 – 0.8)  0.006 0.5 (0.2 – 0.9) 0.035 
Patients followed by PC team  (n=32) (n=268)     Hosmer & Lemeshow 0.61† 
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Goodness-of-Fit Test 
Survival after 1st intervention of PC 
team, median (Q1-Q3) 
 
27 
 
(6-52) 
 
53 
 
(19-126) 
 
0.96 
 
(0.90 – 1.01)* 
 
0.132 
 
1.0 
 
(0.9 – 1.0)* 0.50 
Onco - palliative meeting (OPM)           
    No£ 23 (72) 134 (50) 1.0 -  1.0 -  
    Yes 9 (28) 134 (50) 0.4 (0.2 – 0.9) 0.023 0.4 (0.1 – 1.2) 0.089 
Performance status at first intervention 
of PC team  
         
 
     1-2£ 10 (31) 100 (37) 1.0 -  1.0 -  
     3-4   15 (47) 106 (40) 1.4 (0.6 – 3.3) 0.42 0.9 (0.3 – 2.3) 0.76 
‡ Odds Ratio for receiving chemotherapy versus No chemotherapy in the last 14 days of life. For multiple comparisons testing difference with the reference 
category (primary cancer site, survival after last chemotherapy, acute care admission), p-values were adjusted using Dunnett correction. For the subgroup of 
patients followed by PC team, the multivariable logistic regression models included age, gender, primary cancer site, and training of referent physician in 
PC. 
† The null hypothesis cannot be rejected, indicating that the model fits the data (small p-values indicate a lack of fit of the model). 
$ for 10 years increase of age. 
£ Reference category for univariable and multivariable logistic regression. For cancer site, we chose the cancer site with the lowest risk of dying at 
home or hospice as reference category in order to facilitate interpretation (odds ratio greater than one). In univariable analysis, this category was “melanoma” 
and we used it as reference category for all analyses. 
* for 14 days increase of survival. 
 
 DISCUSSION 
In this study we retrospectively analyzed a case series of 521 deceased cancer patients to 
evaluate the impact of oncologist’s awareness in palliative care (PC), timing of the PC team 
intervention, and multidisciplinary decision-making on process quality indicators of end of 
life care. We found that the active collaboration between referent physicians and PC team, 
through weekly OPMs was the unique independent factor decreasing the odds of dying at 
hospital (excluding hospice) by 70% and decreasing the odds of receiving chemotherapy in 
last 14 days of life by 60%. These effect sizes are of clinical importance for both palliative 
care specialists and oncologists. The clinical intervention of PC team was not significantly 
associated with any indicators. However, in the subgroup of patients who were seen by the PC 
team, patients discussed in OPM were seen earlier by the PC team (better performance status 
at first contact and longer follow up before death). Knowing that the PC team can be 
sollicitated by two different ways (through the OPM or on demand) our data show that the 
first mode of referral favors timely intervention of PC team. To our knowledge, no such data 
has been published in the context of a European cancer care health organisation.  
While evaluating the performance of a given structure of care, it is necessary to account for 
all decedents among patients who have been cared for in this structure. The choice of a 
follow-back of decedents approach does not account for all patients prospectively expected to 
die, but rather for all patients deceased during a given period of time [12-14]. Interestingly, 
retrospective and prospective measures of Earle’s indicators identified similar patterns of end-
of-life care [15]. However in our study, for 14.8% patients, whose vital status could not be 
found in hospital records, incomplete administrative data made it impossible to request civil 
services for vital status. Some of these patients could have died during the study period. It is 
difficult to make any assumptions concerning their location of death. Home palliative care 
services are not highly developed in France and have to be sollicitated by hospital-based PC 
 teams, at discharge of patient. Patients who have not been referred to and followed by any PC 
team during their hospital stay are therefore unlikely to be referred to any home care services. 
Conversely, when lost to follow up by hospital teams, they can die at home or in another 
acute care hospital as well. The underestimation of the proportion of patients who died at 
home, in remaining data should therefore be slight, if it exists.  
Compared to the standards proposed by Earle et al [9] (less than 17% of deaths in acute care 
hospital, less than 10% of patients still treated within 14 days before death, and less than 4% 
of patients having visited ER more than once within last month of life), our data showed 
respectively 58%, 14% and 5% for the three indicators. Concerning the location of death, 
preference to die at home is often reported as a goal of care [16]. However, the congruence of 
preferred and actual place of death is rarely good [17]. The Dying Well in Europe study [18] 
showed the high variability of rates of death at home in cancer patients across European 
countries (from 12% to 45%).  
Although the components of the early PC consultation have been described in more detail, as 
well as the patient's factors associated with its duration [19][20], the respective roles of the 
earliness of consultation and of the actual sharing of decision-making between PC specialists 
and oncologists remained unexplored. As stated by ASCO back in 1998, it is the oncologist’s 
responsibility “to care for their patients in a continuum that extends from the moment of 
diagnosis throughout the course of illness" [21]. Systematic early PC consultation may make 
it more difficult for them not to withdraw (or be withdrawn) from care relationship at the end 
of life. Despite recent progress [22], oncologists still refer their patients to the PC team late in 
the trajectory of illness [2]. The role of the oncologist is known to be crucial for integrating 
PC in oncology practice [23]. Kao et al. [24] found that the oncologist was the only predictor 
for continuing chemotherapy in the last 4 weeks of life. In our organisation, the OPM allows 
to systematically discuss goals of care and to anticipate the difficult period of transition of 
 care. The continuous collaboration of the PC team with oncologists facilitates its early 
intervention. Temel et al. [3] demonstrated in a randomized control trial the effectiveness of 
early and longitudinal participation of  the PC team in newly diagnosed metastatic NSCLC is 
decreasing aggressive care, lowering the rate of depression and increasing quality of life and 
survival. We assume that, in the setting of this trial, oncologists adhered to the concept of 
early PC.  
Improving the quality of outcome in end-of-life patients requires clinical research in two 
different directions: the first is to improve the ability of the physicians to evaluate the 
prognosis and life-expectancy of advanced cancer patients. Several clinical and biological 
parameters have been shown to correlate with very poor survival and several simple scores 
have been described [25-27] and are under prospective evaluation. The second direction is to 
define and evaluate the organisation and procedures the most susceptible to impact quality of 
care and patient outcomes. Rigorous evaluation requires both actual implementation of these 
procedures and use of validated indicators to account for quality of care. This paper 
participates to this research providing with the first measure of such indicators in a French 
centre and showing the critical role of the OPM. To initiate OPMs appears more important 
than the PC training of the referent physician (although it helps to introduce the model), and 
more important than the timing of entry of the PC team. Indeed, early PC is much easier and 
more effective, if preceded by a shared decision on the treatment strategy. A multicentric 
study is underway in the Paris area to collect data, from various cancer care centres where the 
organisation of PC highly differs from one another. This study should provide more results to 
evaluate both the pertinence and external validity of Earle’s indicators and to evaluate the 
impact of different organisations of care. 
In conclusion, our results indicate that a weekly meeting with PC team and oncology staff 
offering a multidisciplinary decision-making for non-curable patients is critical factor to 
 improve quality indicators. This suggests that beyond the earliness of clinical intervention of 
PC team, the quality of collaboration and the structuring of discussion may be a necessary 
condition to integrate palliative care in oncology. Early “seed” of the PC team is necessary 
but not sufficient. Support by the oncologic “soil” is needed and lead to integrative medicine. 
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 Figure and Tables 
 
Figure 1 : Flow diagram for selection of decedents 
 
Figure 2: Flow chart of organisation of care 
 
* 16/64 of these patients discussed at the OPM, were actually followed by specialist referent 
physicians who did not participate to the OPM. These patients happened to be referred to 
oncology day care unit for chemotherapy administration and their case were brought up at the 
OPM by residents in charge of this unit. 
 
 
 
 
 
 
